J2277 Injection, motixafortide, 0.25 mg
Billable / valid for submission HCPCS Release 2026Q3
Short description: Inj, motixafortide, 0.25 mg
Version history
| Release | Valid from | Valid to | Description | Billable |
|---|---|---|---|---|
| 2026Q3 | 2026-07-01 | current | Injection, motixafortide, 0.25 mg | yes |
Related codes in J22
- J2210 Injection, methylergonovine maleate, up to 0.2 mg
- J2212 Injection, methylnaltrexone, 0.1 mg
- J2246 Injection, micafungin in sodium (baxter), not therapeutically equivalent to j2248, 1 mg
- J2247 Injection, micafungin sodium (par pharm) not thereapeutically equivalent to j2248, 1 mg
- J2248 Injection, micafungin sodium, 1 mg
- J2249 Injection, remimazolam, 1 mg
- J2250 Injection, midazolam hydrochloride, per 1 mg
- J2251 Injection, midazolam in 0.9% sodium chloride, intravenous, not therapeutically equivalent to j2250, 1 mg
- J2252 Injection, midazolam in 0.8% sodium chloride, intravenous, not therapeutically equivalent to j2250, 1 mg
- J2253 Injection, midazolam (seizalam), 1 mg
- J2260 Injection, milrinone lactate, 5 mg
- J2265 Injection, minocycline hydrochloride, 1 mg
- J2267 Injection, mirikizumab-mrkz, 1 mg
- J2270 Injection, morphine sulfate, up to 10 mg
- J2272 Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg
- J2274 Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg
- J2278 Injection, ziconotide, 1 microgram
- J2280 Injection, moxifloxacin, 100 mg
- J2281 Injection, moxifloxacin (fresenius kabi), not therapeutically equivalent to j2280, 100 mg
- J2290 Injection, nafcillin sodium, 20 mg